Last reviewed · How we verify

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab

Lund University Hospital · Phase 3 active Small molecule

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is a anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor Small molecule drug developed by Lund University Hospital. It is currently in Phase 3 development for Metastatic breast cancer, Advanced ovarian cancer, Non-small cell lung cancer. Also known as: anthracycline, taxane, platinum.

Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells.

Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells. Used for Metastatic breast cancer, Advanced ovarian cancer, Non-small cell lung cancer.

At a glance

Generic nameepirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab
Also known asanthracycline, taxane, platinum
SponsorLund University Hospital
Drug classanthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor
TargetDNA, microtubules, PD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Epirubicin, cyclophosphamide, paclitaxel, and carboplatin work by targeting rapidly dividing cancer cells. Epirubicin and cyclophosphamide induce DNA damage, while paclitaxel prevents cell division. Carboplatin also induces DNA damage. Pembrolizumab enhances the body's immune response against cancer cells by blocking the PD-1 receptor, allowing T-cells to attack cancer cells more effectively.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab

What is epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is a anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor drug developed by Lund University Hospital, indicated for Metastatic breast cancer, Advanced ovarian cancer, Non-small cell lung cancer.

How does epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab work?

Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells.

What is epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab used for?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is indicated for Metastatic breast cancer, Advanced ovarian cancer, Non-small cell lung cancer, Triple-negative breast cancer.

Who makes epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is developed by Lund University Hospital (see full Lund University Hospital pipeline at /company/lund-university-hospital).

Is epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab also known as anything else?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is also known as anthracycline, taxane, platinum.

What drug class is epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab in?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab belongs to the anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor class. See all anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor drugs at /class/anthracycline-antibiotic-alkylating-agent-taxane-platinum-based-alkylating-agent-pd-1-inhibitor.

What development phase is epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab in?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab is in Phase 3.

What are the side effects of epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab?

Common side effects of epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab include Neutropenia, Anemia, Thrombocytopenia, Fatigue, Nausea, Vomiting.

What does epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab target?

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab targets DNA, microtubules, PD-1 and is a anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor.

Related